

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

- 1-5. (Cancelled)
6. (Previously Presented) An isolated antibody or fragment thereof that specifically binds to a polypeptide consisting of the sequence of SEQ ID NO:43.
7. (Previously Presented) An isolated antibody or fragment thereof that specifically binds to a polypeptide consisting of the sequence of SEQ ID NO:7.
8. (Previously Presented) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof is an Fab fragment, an Fab' fragment, or an F(ab')₂ fragment.
9. (Currently Amended) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof is an F(v) fragment,~~a heavy chain monomer, a heavy chain dimer, a heavy chain trimer, a light chain monomer, a light chain dimer, a light chain trimer, or and a dimer consisting of one heavy and one light chain.~~
10. (Previously Presented) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof is a monoclonal antibody.
11. (Previously Presented) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof blocks binding of low density lipoprotein (LDL) to the polypeptide.

12-19. (Cancelled)

20. (Previously Presented) A humanized, chimeric, or human antibody or fragment thereof that specifically binds to a polypeptide consisting of the sequence of SEQ ID NO:43.

21. (Previously Presented) A humanized, chimeric, or human antibody or fragment thereof that specifically binds to a polypeptide consisting of the sequence of SEQ ID NO:7.

22. (Previously Presented) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof is an Fab fragment, an Fab' fragment, or an F(ab')₂ fragment.

23. (Currently Amended) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof is an F(v) fragment, ~~a heavy chain monomer, a heavy chain dimer, a heavy chain trimer, a light chain monomer, a light chain dimer, a light chain trimer, or a dimer consisting of one heavy and one light chain.~~

24. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof is a humanized antibody or fragment thereof.

25. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof is a chimeric antibody or fragment thereof.

26. (Original) The antibody or fragment thereof of claim 25, wherein the chimeric antibody or fragment thereof contains a constant region derived from a human antibody and a variable region derived from a mouse antibody.

27. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof is a human antibody or fragment thereof.

28. (Previously Presented) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof blocks binding of LDL to the polypeptide.

29-30. (Cancelled)

31. (Previously Presented) A preparation of polyclonal antibodies that specifically bind to a polypeptide consisting of the sequence of SEQ ID NO:43.

32. (Previously Presented) A preparation of polyclonal antibodies that specifically bind to a polypeptide consisting of the sequence of SEQ ID NO:7.

33. (Previously Presented) The preparation of claim 32, wherein the antibodies block binding of LDL to the polypeptide.

34-38. (Cancelled)

39. (Original) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof comprises a label.

40. (Original) The antibody or fragment thereof of claim 39, wherein the label is a radiolabel.

41. (Original) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof comprises a technetium-binding ligand.

42. (Original) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof comprises a gadolinium-binding chelator.

43. (Previously Presented) The antibody or fragment thereof of claim 42, wherein the gadolinium-binding chelator is diethylene triamine penta-acetic acid (DTPA).

44-48. (Cancelled)

49. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof comprises a label.

50. (Original) The antibody or fragment thereof of claim 49, wherein the label is a radiolabel.

51. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof comprises a technetium-binding ligand.

52. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof comprises a gadolinium-binding chelator.

53. (Original) The antibody or fragment thereof of claim 52, wherein the gadolinium-binding chelator is DTPA.

54. (Cancelled)

55. (Original) A pharmaceutical composition comprising the antibody or fragment thereof of claim 7 and a pharmaceutically acceptable carrier.

56. (Cancelled)

57. (Original) A pharmaceutical composition comprising the antibody or fragment thereof of claim 21 and a pharmaceutically acceptable carrier.

58-59. (Cancelled)

60. (Original) A cell line that produces the antibody of claim 7.

61. (Original) The cell line of claim 60, wherein the cell line is a hybridoma.

62-63. (Cancelled)

64. (Original) A cell line that produces the antibody of claim 21.

65. (Original) The cell line of claim 64, wherein the cell line is a hybridoma.

66-71. (Cancelled)

72. (Previously Presented) A pharmaceutical composition comprising the antibody or fragment thereof of claim 6 and a pharmaceutically acceptable carrier.

73. (Previously Presented) A pharmaceutical composition comprising the antibody or fragment thereof of claim 20 and a pharmaceutically acceptable carrier.

74. (Previously Presented) A cell line that produces the antibody of claim 6.

75. (Previously Presented) The cell line of claim 74, wherein the cell line is a hybridoma.

76. (Previously Presented) A cell line that produces the antibody of claim 20.

77. (Previously Presented) The cell line of claim 76, wherein the cell line is a hybridoma.